{"id":6357,"date":"2025-04-08T18:20:21","date_gmt":"2025-04-08T15:20:21","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=6357"},"modified":"2025-04-08T18:20:21","modified_gmt":"2025-04-08T15:20:21","slug":"summary-reverse-it-trial-acc-25-reversal-if-ticagrelors-antiplatelet-effects-in-urgent-surgery-or-major-bleeding-source-acc-25-scientific-session-presented-by-dr-deepak-bhatt","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/summary-reverse-it-trial-acc-25-reversal-if-ticagrelors-antiplatelet-effects-in-urgent-surgery-or-major-bleeding-source-acc-25-scientific-session-presented-by-dr-deepak-bhatt\/","title":{"rendered":"Summary: REVERSE-IT Trial \u2013 ACC.25 (Reversal if Ticagrelor\u2019s Antiplatelet Effects in Urgent Surgery or Major Bleeding) Source: ACC.25 Scientific Session, presented by Dr. Deepak Bhatt (New York, NY, USA) Date: March 2025"},"content":{"rendered":"<div>Summary: REVERSE-IT Trial \u2013 ACC.25<\/div>\n<div>(Reversal if Ticagrelor\u2019s Antiplatelet Effects in Urgent Surgery or Major Bleeding)<\/div>\n<div>Source: ACC.25 Scientific Session, presented by Dr. Deepak Bhatt (New York, NY, USA)<\/div>\n<div>Date: March 2025<\/div>\n<div><\/div>\n<div>Bentracimab Rapidly Reverses Ticagrelor\u2019s Antiplatelet Effects in Urgent Surgery or Major Bleeding<\/div>\n<div><span> 1. Background:<\/span><\/div>\n<div><span> \u2022 Ticagrelor is a potent oral P2Y\u2081\u2082 inhibitor with no available reversal agent via platelet transfusion.<\/span><\/div>\n<div><span> \u2022 Bentracimab is a recombinant human monoclonal antibody designed to reverse ticagrelor\u2019s antiplatelet activity.<\/span><\/div>\n<div><span> 2. Study Design:<\/span><\/div>\n<div><span> \u2022 Phase 3, prospective, open-label, single-arm, multicenter REVERSE-IT trial.<\/span><\/div>\n<div><span> \u2022 Included 226 ticagrelor-treated patients needing urgent surgery (n=141) or experiencing major bleeding (n=71).<\/span><\/div>\n<div><span> \u2022 Bentracimab was administered via IV infusion.<\/span><\/div>\n<div><span> 3. Primary Endpoint:<\/span><\/div>\n<div><span> \u2022 Reversal of ticagrelor effect within 4 hours measured by VerifyNow P2Y\u2081\u2082 assay.<\/span><\/div>\n<div><span> \u2022 Achieved in all groups with statistical significance (P&lt;0.0001).<\/span><\/div>\n<div><span> 4. Secondary Endpoint (Effective Hemostasis):<\/span><\/div>\n<div><span> \u2022 Achieved in:<\/span><\/div>\n<div><span> \u2022 94.3% of total patients<\/span><\/div>\n<div><span> \u2022 100% of surgery patients<\/span><\/div>\n<div><span> \u2022 83.1% of bleeding patients<\/span><\/div>\n<div><span> \u2022 All results were statistically significant (P&lt;0.0001).<\/span><\/div>\n<div><span> 5. Safety:<\/span><\/div>\n<div><span> \u2022 Drug-related adverse events:<\/span><\/div>\n<div><span> \u2022 2.2% overall<\/span><\/div>\n<div><span> \u2022 No serious drug-related adverse events or treatment discontinuations.<\/span><\/div>\n<div><span> 6. Regulatory Note:<\/span><\/div>\n<div><span> \u2022 Bentracimab recently received orphan drug designation from the FDA.<\/span><\/div>\n<div><\/div>\n<div>Conclusion:<\/div>\n<div>Bentracimab provided rapid and sustained reversal of ticagrelor\u2019s antiplatelet effects with high rates of effective hemostasis and a strong safety profile, offering a critical breakthrough for managing urgent surgery or bleeding in ticagrelor-treated patients.<\/div>\n<div><\/div>\n<div><a href=\"https:\/\/evidence.nejm.org\/doi\/pdf\/10.1056\/EVIDoa2100047\">https:\/\/evidence.nejm.org\/doi\/pdf\/10.1056\/EVIDoa2100047<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Summary: REVERSE-IT Trial \u2013 ACC.25 (Reversal if Ticagrelor\u2019s Antiplatelet Effects in Urgent Surgery or Major Bleeding) Source: ACC.25 Scientific Session, presented by Dr. Deepak Bhatt (New York, NY, USA) Date: March 2025 Bentracimab Rapidly Reverses Ticagrelor\u2019s Antiplatelet Effects in Urgent Surgery or Major Bleeding 1. Background: \u2022 Ticagrelor is a potent oral P2Y\u2081\u2082 inhibitor with [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6357","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6357"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6357\/revisions"}],"predecessor-version":[{"id":6358,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6357\/revisions\/6358"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}